List view / Grid view
Out of the US, a newly developed a rapid, stain-free, and automated viral plaque detection system enabled by holography and deep learning, is a cost-effective way of observing the formation of viral plaques caused by viral infections over a layer of cells.
Scientists have discovered that a vaccinated San Diego resident has produced antibodies that are effective against multiple variants of SARS-CoV-2, including Omicron. The research also identified three antibodies that can neutralise the virus, giving new insights into different binding mechanisms with the SARS-CoV-2 spike protein. The findings could help to…
US researchers have found that increasing the expression of the enzyme serine racemase in the prefrontal cortex of middle-aged rats can enhance cognitive function.
As new variants of the SARS-CoV-2 virus emerge, leading scientists Dr Oscar Bastidas and Dr Zoran Sevarac explore how their latest research identified a structured frequency domain profile in data with no discernible pattern. Their article also emphasises that it remains imperative to continue learning about this pathogen’s molecular machinery…
Brad Sorenson, CEO of Providence Therapeutics, shares the future developments and exciting potential of mRNA therapies, including improved efficacy and wider access to vaccines, and future promise for cancer treatment.
US scientists have developed new mRNA vaccines for Zika virus and HIV-1 that produce a strong mother-to-child transmission of antibodies, in rabbits.
In this ebook are articles on the future potential for mRNA therapies and combatting new variants of the SARS-CoV-2.
The Omicron variant of the SARS CoV-2 virus has previously had a number of break-through infections. However, researchers have discovered that antibodies present in previously infected patients can neutralise variants of the COVID-19 disease.
The researchers say their new discovery could be used to design better vaccines and to gain a deeper insight into autoimmune diseases and allergies.
Australian researchers have uncovered why some forms of Streptococcus A (Strep A) are associated with severe invasive infection.
The resulting compounds, which can bind to spike proteins from the original coronavirus, could serve as a starting point for developing broad-spectrum treatments for COVID-19.
Drug Target Review’s Izzy Wood spoke to Joseph Hernandez, CEO of Blue Water Vaccines, about developing transformational vaccines to address significant health challenges globally.
US scientists have designed a mathematical model that can predict COVID-19 vaccines’ effectiveness over the long term in healthy individuals and those who have cancer or suppressed immune responses.
US researchers develop a dual-action cell therapy engineered to eliminate established tumours and train the immune system to eradicate primary tumour and prevent cancer’s recurrence.
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
